Screener
Veracyte VCYT Business Segments — Direct expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Veracyte in its filing.
Tagged under the XBRL concept vcyt:DirectOperatingExpenses.
The source filing: Veracyte’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 8:07 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001384101-26-000031
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development: | ||
| Compensation expense | 15,547 | 9,748 |
| Direct research and development expense | 4,198 | 4,141 |
| Other research and development expenses (4) | 5,460 | 1,815 |
| Allocation of facilities and IT expenses | 1,893 | 2,016 |
| Total research and development | 27,098 | 17,720 |
| Selling and marketing: |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Veracyte's business segments — direct expense?
- Veracyte (VCYT) reported business segments — direct expense of $4.2M in Q1 2026.
- How has Veracyte's business segments — direct expense changed year-over-year?
- Veracyte's business segments — direct expense increased by 1.4% year-over-year, from $4.14M to $4.2M.
- What is the long-term trend for Veracyte's business segments — direct expense?
- Over 3 years (2022 to 2025), Veracyte's business segments — direct expense has grown at a 39.3% compound annual growth rate (CAGR), from $6.14M to $16.6M.
- What does business segments — direct expense mean?
- Represents the specific, traceable operating costs directly incurred by the reportable segment to support its business activities. This metric helps isolate the segment's operational footprint from shared corporate overhead.
Ask your AI about Veracyte's business segments — direct expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude